 cyclic-altern versu response-ori chemotherapi small-cel lung cancer german multicent trial patient chemotherapi favor treatment modal small-cel lung cancer sclc patient fix cyclic-altern treatment ifosfamide/etoposid IE doxorubicin vincristin cav response-ori treatment IE therapi respons immedi switch cav arm cycl interv chemotherapi patient limited-stag diseas irradi Gy prophylact cranial irradi Gy complet respond mainten therapi patient complet respons minimum follow-up year assess patient overal respons rate cyclic altern response-ori treatment complet remiss CR rate median surviv time month cyclic-altern versu month response-ori treatment surviv rate limited-stag diseas LD patient median surviv month month surviv rate extensive-stag diseas ED patient median surviv versu month surviv rate result cyclic-altern treatment hypothesi goldi al advantag comparison sequenti treatment strategi immedi switch second-lin protocol time respons first-lin therapi major aim treatment sclc activ regimen time cours treatment regardless sequenti therapi